Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Menorrhagia Clear all
Terminated No phase listed Observational

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

NCT05026502
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding

NCT04205266
View directory record Official record
Conditions
Anemia, Iron Deficiency, Heavy Menstrual Bleeding
Interventions
Ferumoxytol, Ferrous Sulfate
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Truclear on Patient Quality of Life

NCT02934789
View directory record Official record
Conditions
Heavy Menstrual Bleeding
Interventions
Hysteroscopic myomectomy with Truclear, Medical therapy
Procedure · Drug
Lead sponsor
All For Women Healthcare, Illinois
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

Post Approval NovaSure Essure Labeling Study

NCT01934244
View directory record Official record
Conditions
Menorrhagia
Interventions
NovaSure Endometrial Ablation
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
14
States / cities
Chandler, Arizona • Arvada, Colorado • Sarasota, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding

NCT02842736
View directory record Official record
Conditions
Menorrhagia
Interventions
Cerene(R) Cryotherapy Device
Device
Lead sponsor
Channel Medsystems
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Arlington Heights, Illinois • Naperville, Illinois • Fort Wayne, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

Low VW Activity in Adolescent HMB

NCT02933411
View directory record Official record
Conditions
Von Willebrand Factor Deficiency
Interventions
Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated No phase listed Observational

Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding

NCT05685199
View directory record Official record
Conditions
Hypermobile Ehlers-Danlos Syndrome, Heavy Menstrual Bleeding, Hypermobility Syndrome (Disorder)
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
12 Years to 40 Years · Female only
Enrollment
15 participants
Timeline
2024 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women

NCT03886220
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Elagolix, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
45
States / cities
Birmingham, Alabama • Searcy, Arkansas • La Mesa, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System

NCT00094536
View directory record Official record
Conditions
Menorrhagia
Interventions
Extended treatment regimen using Her Option Cryotherapy
Device
Lead sponsor
CooperSurgical Inc.
Industry
Eligibility
30 Years to 100 Years · Female only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
7
States / cities
Phoenix, Arizona • Wellington, Florida • Burlington, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Minimize Menorrhagia in Women With Von Willebrand Disease

NCT02606045
View directory record Official record
Conditions
Von Willebrand Diseases
Interventions
recombinant von Willebrand factor, tranexamic acid
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
13 Years to 45 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
19
States / cities
Gilbert, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional Results available

Doppler-Guided Uterine Artery Occlusion (DUAO) Device for Fibroid Related Bleeding

NCT00496080
View directory record Official record
Conditions
Menorrhagia, Uterine Fibroids
Interventions
Doppler-Guided Uterine Artery Occlusion Device (DUAO)
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Mirena Extension Trial

NCT02985541
View directory record Official record
Conditions
Contraception
Interventions
Levonorgestrel IUS (Mirena, BAY86-5028)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
49
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of a Levonorgestrel 52 mg Intrauterine System for the Treatment of Heavy Menstrual Bleeding

NCT03642210
View directory record Official record
Conditions
Menorrhagia
Interventions
Levonorgestrel 52 mg intrauterine system
Combination Product
Lead sponsor
Medicines360
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
29
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Sleep and Health Outcomes in Women With Heavy Menses

NCT05722444
View directory record Official record
Conditions
Menstruation; Heavy
Interventions
Nighttime Feminine Product
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Copper IUD Treatment Observation Study

NCT02519231
View directory record Official record
Conditions
Menorrhagia
Interventions
Naproxen, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Chicago, Illinois • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Withdrawn No phase listed Observational

A Study to Evaluate Changes in Hair in Adult Participants Taking Oral Oriahnn Capsules With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)

NCT06058728
View directory record Official record
Conditions
Uterine Fibroids (UF)
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT03049735
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroid
Interventions
Relugolix, Estradiol/norethindrone acetate, Estradiol/norethindrone acetate placebo, Relugolix placebo
Drug
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
76
States / cities
Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Post Market TRUST - U.S.A. Study

NCT02163525
View directory record Official record
Conditions
Symptomatic Uterine Fibroids
Interventions
Global Fibroid Ablation (GFA), Abdominal or Laparoscopic Myomectomy, Uterine Artery Embolization (UAE)
Procedure
Lead sponsor
Acessa Health, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
9
States / cities
Santa Monica, California • Walnut Creek, California • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)

NCT03400956
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Vilaprisan (BAY1002670), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Canyon Country, California • Encinitas, California • Huntington Park, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Results available

Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding

NCT01190150
View directory record Official record
Conditions
Menorrhagia
Interventions
tranexamic acid
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
12 Years to 16 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

NCT02925494
View directory record Official record
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Interventions
Estradiol/Norethindrone Acetate, Elagolix
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

NCT01391052
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Hypermenorrhea
Interventions
Norethindrone acetate pretreatment, No pretreatment
Drug · Other
Lead sponsor
Scott and White Hospital & Clinic
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Temple, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2011 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Registry Study of Genesys HTA for Treatment of Menorrhagia

NCT01197547
View directory record Official record
Conditions
Menorrhagia
Interventions
Genesys HTA
Device
Lead sponsor
Minerva Surgical, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
19
States / cities
San Diego, California • Newark, Delaware • Athens, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 17, 2026, 5:15 AM EDT